Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common blood pressure drug shrink kidney tumors?

NCT ID NCT02104011

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether propranolol, a beta-blocker, could shrink or stabilize kidney angiomyolipomas in people with tuberous sclerosis. Only 2 participants were enrolled before the trial was terminated, so the results are very limited. The goal was to find a less invasive alternative to surgery or embolization.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Propranolol (a beta-blocker, commonly used for high blood pressure)
What this could lead to
If it works, this could point toward a non-invasive treatment option for kidney tumors in tuberous sclerosis, potentially avoiding surgery or embolization.
What could go wrong
This was a very small pilot trial with only 2 participants and was terminated early, so results are not reliable. Beta-blockers may not shrink these tumors, and side effects like low blood pressure or fatigue are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

2 people

The number who actually took part.

Started

May 2015

Finished

Nov 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Tuberous sclerosis patients with one or several angiomyolipomas of a size of at least 4 cms. Exclusion Criteria: * Patients whom CT or MR scan shows one or several intra-lesional aneurisms requiring a preventive embolization. * Patients with a retroperitoneal hemorragic complication requiring a preventive embolization. * Patients whom biopsy will show an adenocarcinoma, hypertension non controlled, renal failure and severe liver. * Diabetic subjects insufficiently controlled. * Beta-blockers contra-indication. * Psychosis, severe mental disorder. * Patient already treated with beta-blockers or mTOR inhibitors. * Pregnant or nursing women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal angiomyolipomas are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney angiomyolipoma tuberous sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal angiomyolipomas Tuberous sclerosis

Contacts and locations

Locations

  • Nephrology department

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.